We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

173 hedge funds and large institutions have $721M invested in Avadel Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 51 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 51

18% more capital invested

Capital invested by funds: $613M → $721M (+$108M)

3.62% more ownership

Funds ownership: 80.58% → 84.2% (+3.6%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

4% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 28

1% less funds holding

Funds holding: 175 → 173 (-2)

38% less call options, than puts

Call options by funds: $2.43M | Put options by funds: $3.91M

Holders
173
Holders Change
-2
Holders Change %
-1.14%
% of All Funds
2.28%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
27
Increased
69
Reduced
51
Closed
28
Calls
$2.43M
Puts
$3.91M
Net Calls
-$1.48M
Net Calls Change
+$257K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$14.6M
2
BlackRock
BlackRock
New York
+$11.9M
3
TSC
Two Seas Capital
New York
+$10.6M
4
TLP
Tri Locum Partners
New York
+$8.91M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.6M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$21.6M
2
Bank of America
Bank of America
North Carolina
-$8.56M
3
GJL
Gendell Jeffrey L
-$8.35M
4
Citadel Advisors
Citadel Advisors
Florida
-$6.3M
5
UBS Group
UBS Group
Switzerland
-$3.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
26
Samsara BioCapital
California
$5.98M -$2.57M -292,023 -30%
KCM
27
Knoll Capital Management
Florida
$5.31M – – –
MWM
28
Modera Wealth Management
New Jersey
$4.95M -$44 -5 -0%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$4.61M +$2.11M +240,599 +86%
TI
30
Trexquant Investment
Connecticut
$4.28M +$3.11M +354,221 +274%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$3.87M -$502K -57,123 -12%
DMKJ
32
David M. Knott Jr
$3.77M – – –
Goldman Sachs
33
Goldman Sachs
New York
$3.73M -$2.69M -306,585 -42%
Ameriprise
34
Ameriprise
Minnesota
$3.57M +$251K +28,592 +8%
AIC
35
AWM Investment Company
New York
$2.8M +$2.42M +275,189 +671%
Nuveen
36
Nuveen
North Carolina
$2.62M -$1.95M -221,916 -43%
DFCM
37
Dark Forest Capital Management
Puerto Rico
$2.61M +$1.02M +115,699 +64%
CSS
38
Cubist Systematic Strategies
Connecticut
$2.42M +$1.08M +123,285 +82%
CM
39
Caption Management
Oklahoma
$2.34M – – –
JGC
40
J. Goldman & Co
New York
$2.33M +$416K +47,363 +22%
Renaissance Technologies
41
Renaissance Technologies
New York
$2.24M -$768K -87,400 -26%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$2.23M +$156K +17,719 +8%
IAM
43
Iridian Asset Management
Connecticut
$2.21M – – –
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$1.97M -$18.7K -2,130 -0.9%
NPT
45
National Philanthropic Trust
Pennsylvania
$1.94M – – –
MML Investors Services
46
MML Investors Services
Massachusetts
$1.83M +$115K +13,072 +7%
Point72 Asset Management
47
Point72 Asset Management
Connecticut
$1.79M +$859K +97,730 +93%
Barclays
48
Barclays
United Kingdom
$1.62M -$1.34M -152,067 -45%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.49M – – –
Fidelity Investments
50
Fidelity Investments
Massachusetts
$1.29M -$664K -75,611 -34%
1
2
3 4 5

AVDL Hedge Fund Activity: Q2 2025 in Review

173 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2025, worth a combined $721M — up 18% from $613M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of AVDL and 27 opened new positions — a net loss of 1 holder — while 51 trimmed existing stakes and 69 added.

The largest buyer was Vanguard Group, adding an estimated $14.6M. The largest seller was Janus Henderson Group, cutting an estimated $21.6M.

  • 173 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2025, down from 175 in Q1 2025.
  • Funds reported $721M of Avadel Pharmaceuticals stock for Q2 2025, up 18% quarter-over-quarter.
  • 27 funds opened new Avadel Pharmaceuticals positions in Q2 2025 and 28 closed out, a net change of -1 holder.
  • The largest Avadel Pharmaceuticals buyer in Q2 2025 was Vanguard Group, an estimated $14.6M added.
  • The largest Avadel Pharmaceuticals seller in Q2 2025 was Janus Henderson Group, an estimated $21.6M sold.

Based on aggregated 13F filings for Q2 2025.